{"id":"shigella-conjugate-vaccines","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL409755","moleculeType":"Small molecule","molecularWeight":"4752.80"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"These vaccines work by presenting Shigella lipopolysaccharide (LPS) or other surface antigens conjugated to carrier proteins, which enhances T-cell dependent immune responses and generates both humoral and cellular immunity. The conjugate approach improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in younger populations. This elicits protective antibodies that prevent Shigella infection and associated dysentery.","oneSentence":"Shigella conjugate vaccines stimulate the immune system to produce antibodies against Shigella bacterial antigens by conjugating polysaccharide antigens to protein carriers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:15.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Shigella infection and shigellosis (bacterial dysentery)"}]},"trialDetails":[{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT07205926","phase":"PHASE1","title":"First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults","status":"RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-10-09","conditions":"Shigella, Diarrhea","enrollment":60},{"nctId":"NCT04078022","phase":"PHASE2","title":"Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-03-02","conditions":"Shigella","enrollment":58},{"nctId":"NCT04602975","phase":"PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a","status":"COMPLETED","sponsor":"Institut Pasteur","startDate":"2020-10-06","conditions":"Healthy","enrollment":248},{"nctId":"NCT01369927","phase":"PHASE1","title":"Shigella Sonnel O-SPC/rBRU Conjugate Vaccine","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2011-05-15","conditions":"Immunogenicity, Shigellosis","enrollment":60},{"nctId":"NCT02797236","phase":"PHASE1","title":"SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Institut Pasteur","startDate":"2016-09","conditions":"Shigellosis, Bacillary Dysentery","enrollment":64},{"nctId":"NCT01399424","phase":"PHASE1","title":"Shigella Sonnei OSPC-rDT Conjugate Vaccine","status":"WITHDRAWN","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2011-07-16","conditions":"Shigellosis","enrollment":""},{"nctId":"NCT00368316","phase":"PHASE3","title":"Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2003-01","conditions":"Shigellosis","enrollment":2799},{"nctId":"NCT01069471","phase":"PHASE1","title":"Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella","status":"COMPLETED","sponsor":"GlycoVaxyn AG","startDate":"2010-02","conditions":"Shigellosis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S. sonnei O-SP-rEPA conjugate.","S. flexneri 2a O-SP-rEPA conjugate."],"phase":"phase_3","status":"active","brandName":"Shigella conjugate vaccines","genericName":"Shigella conjugate vaccines","companyName":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","companyId":"eunice-kennedy-shriver-national-institute-of-child-health-and-human-development","modality":"Biologic","firstApprovalDate":"","aiSummary":"Shigella conjugate vaccines stimulate the immune system to produce antibodies against Shigella bacterial antigens by conjugating polysaccharide antigens to protein carriers. Used for Prevention of Shigella infection and shigellosis (bacterial dysentery).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}